Clinical trial
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand…
NCT00462202 · Keryx Biopharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00462202 |
|---|---|
| Title | Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong |
| Official title | An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients With Persistent Microalbuminuria in Australia, New Zealand, and Hong Kong |
| Lead sponsor | Keryx Biopharmaceuticals, Industry |
| Collaborators | Collaborative Study Group (CSG) |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | sulodexide |
| Enrollment | 200 |
| Start date | Apr 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Apr 18, 2007 |
| Last update posted | Mar 3, 2017 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: